BACKGROUND: Anti-angiogenic biologicals represent an important concept for the treatment of vasoproliferative diseases. However, the need for continued treatment, the presence of nonresponders, and the risk of longterm side effects limit the success of existing therapeutic agents. Although Tspan12 has been shown to regulate retinal vascular development, nothing is known about its involvement in neovascular disease and its potential as a novel therapeutic target for the treatment of vasoproliferative diseases.
A berrant vessel growth and breakdown of the blood retinal barrier are major causes of vision loss in Western countries. 1 Over the past decade, we have seen increasingly successful use of biological agents (eg, function-blocking antibodies) to treat a variety of diseases, including diabetic retinopathy and age-related macular degeneration. Anti-vascular endothelial growth factor (VEGF) antibodies (Abs) that are applied locally by intravitreal injections are highly effective in decreasing vascular permeability of abnormal neovessels, the major cause for vision-limiting retinal edema. However, for the treatment of proliferative diabetic retinopathy, their ability to prevent neovessel formation or induce neovessel regression is limited. 2, 3 Developments of new therapeutic agents that target VEGF-independent endothelial cell proliferation are hence necessary. Combination therapies with complimentary therapeutic agents may greatly improve the therapeutic efficacy of current anti-VEGF treatments. 4, 5 Canonical Wnt signaling, with β-catenin as its key mediator, plays an important role in cell proliferation during development and oncogenesis. 6, 7 In the eye, β-catenin also regulates many developmental processes, including retinal vascular development and blood retinal barrier formation. [8] [9] [10] [11] [12] Wnt signaling is complex. Wnt ligands bind to heterodimeric receptor complexes consisting of Frizzled (FZD) transmembrane proteins and low-density lipoprotein receptor-related protein 5/6 (LRP5/LRP6). 6, 13 Norrin, one of the Wnt-unrelated FZD ligands, requires Tspan12 to activate β-catenindependent signaling.
14 Mutations in the receptor complex (FZD4, LRP5, or Tspan12) cause hereditary retinal diseases, such as familial exudative vitreoretinopathy and Norrie disease, which are characterized by incomplete vascularization of the retina. 15, 16 Loss of function in either of those genes causes severe defects in the development of the retinal vascular bed in mice, [17] [18] [19] whereas activation of β-catenin signaling has been associated with retinal vasoproliferative diseases characterized by excessive vessel growth. 20, 21 Therefore, β-catenin-associated signaling components represent promising therapeutic targets for the treatment of vascular pathologies. [22] [23] [24] However, nonselective targeting of β-catenin signaling poses the risk of uncontrolled off-target effects because β-catenin is a crucial mediator for cell proliferation and differentiation in many different cell types. In contrast, Tspan12 has been shown to be selectively expressed in retinal vascular endothelial cells 14 and hence may present an attractive target to selectively modulate β-catenin-associated endothelial cell proliferation.
Tspan12 belongs to the Tetraspanin (Tspan) family, which mainly includes cell surface proteins characterized by 4 transmembrane domains and 2 extracellular domains. 25 Members of the Tspan family participate in diverse cellular processes and act as signaling platforms by forming Tspan-enriched microdomains in plasma membranes. They have also been associated with several pathological conditions, such as tumor progression (eg, Tspan8 and CD151) and metastasis (eg, CD82 and CD9). 26, 27 Recent discoveries found that Tspan12 is selectively expressed in the retinal vasculature and acts as a key regulator for retinal vascular development by activating β-catenin signaling. 14 Although the involvement of Tspan12 in retinal angiogenesis during development has been previously reported by others, so far no studies have supported its roles in retinal vasoproliferative disease. Here we provide the first evidence for the therapeutic use of a Tspan12-blocking Ab for the treatment of retinal neovascular disease. We have used a powerful and novel phage-displayed combinatorial Ab library for the generation of high-affinity therapeutic Abs. 28 With this technique, Abs can be derived from the human Ab repertoire, a key feature in the development of clinically applicable Abs. 29, 30 We specifically designed a Tspan12-blocking Ab that is capable of interacting with human and mouse Tspan12 antigen so that our newly developed Ab would be applicable for preclinical as well as
Clinical Perspective
What Is New?
• Tspan12/β-catenin signaling plays an important role in the development of vasoproliferative retinopathy.
• We developed a new antibody (anti-Tspan12 Ab 2D10) that showed strong anti-angiogenic effect in vitro and in vivo without inducing negative side effects on retinal functions by blocking Tspan12/ β-catenin signaling.
• Combined treatment of the Ab 2D10 with Aflibercept, a vascular endothelial growth factor inhibitor, showed significant enhancement of the therapeutic effect of each monotherapy.
What Are the Clinical Implications?
• Anti-vascular endothelial growth factor therapeutics have been popularly used for treatment of vasoproliferative retinopathy, but their potential side effects after long-term use and treatment failure in certain patient populations have increased the necessity of alternative therapeutic strategies.
• Targeting the Tspan12/β-catenin signaling pathway with the newly developed anti-Tspan12 Ab 2D10 depicts a complementary therapeutic strategy for human retinal diseases.
• Combination therapy of Ab 2D10 with Aflibercept provides the opportunity to decrease therapeutic doses of anti-vascular endothelial growth factor agents and reduce unwanted side effects.
clinical studies. We provide strong evidence that the Tspan12-blocking Ab prevents development of pathological neovascularization in murine models of proliferative retinopathy. Combination therapy with a known anti-VEGF agent demonstrated significant synergy supporting the potential clinical use of the anti-Tspan12 Ab as novel angiomodulatory agent.
METHODS

Ab Selection
Antigen peptide (CCGVVYFTDWLEMTEMDWPPDSCCVREFP GCSKQAHQEDL-SDLYQEGC) from ECD2 of Tspan12 was synthesized and N-terminally biotinylated. M13 phage was used for display of naïve human combinatorial Ab libraries. The overall phage panning was done as previously described.
28
Measurement of Ab Affinity
The parameters of binding kinetics were determined by biolayer interferometry using Octet Red 96 with streptavidin dip and read biosensors (#18-5021, ForteBio). The biotinylated antigen was used as a ligand loaded onto the biosensor, and Ab was used as an analyte retained in solution. Each Ab was tested in 7 different concentrations. The results were analyzed by the fitting model of 2:1, with full R 2 >0.99.
In Vitro Assays
For the wound healing assay, human umbilical vein endothelial cells (HUVECs; #8000, ScienCell Research Laboratory) were seeded into 96-well ImageLock tissue culture plates (#4379, Essen BioScience). Wound-Maker (#4493, Essen BioScience) was used to create reproducible wounds. Assay plates were analyzed by Incucyte scratch wound cell migration software module (#9600-0012, Essen BioScience) over 24 hours. Percent of closure was calculated by the formula: % of wound healing = 100% x (W0-Wn)/W0 (W0: wound width at 0 hours; Wn: wound width at n hours). For the tube formation assay, HUVECs were applied to Matrigel (#356231, BD Biocoat) in μ-plate angiogenesis 96 well (#89646, Ibidi). Wells were continuously observed by Incucyte Zoom system. Total number of branch points and total tube lengths were calculated by the Wimasis image analysis platform.
In knockdown (KD) experiments, HUVECs were transfected with 20 nmol/L of pooled or single small interfering RNA (siRNA) (Dharmacon) with RNAimax. The on-target-plus-modified pool of siRNA-targeting human Tspan12 (Dharmacon) contained 4 siRNAs with the following target sequences: GGAUAUUGUGGAACGGUGA, CU GUAUAAUUCAGUCGAUU, AGAACUGGCUUGUGGCGUU, and CCUAGAUAUCGGUGGCUUA.
Nontargeting siRNAs were used as negative controls. After 24 hours, cells were seeded on collagen-coated cover slides for immunocytochemistry.
Animal Models.
C57BL/6 and transgenic mice used in these studies were treated in adherence with the National Institutes of /J, The Jackson Laboratory). Intravitreal injections were performed using a 33-gauge sharp Hamilton syringe. Mice received injections with the Ab 2D10, Aflibercept (Eylea, Regeneron Pharmaceuticals), or a combination of both in 1 eye and control injections with rhIgG1 (100 ng, #110-HG-100, R&D Systems) in the partner eye. Time points of the injections and Ab concentrations are indicated in the figures or figure legends. The AngioTool software (National Cancer Institute) 32 was used to quantify branch points during physiological development. In the OIR model, areas of vasoobliteration (VO) and neovascularization (NV) were quantified at OIR P17 according to well-established techniques. 33 VO and NV rescue were determined by normalizing the VO, respectively NV area of treated retinas to the average VO, respectively NV area of IgG1 treated control eyes 
Immunofluorescence Analysis
Eyes were harvested and fixed in 4% paraformaldehyde for 40 minutes for flatmount preparation or flash frozen for cryosectioning. HUVECs were fixed in 100% methanol for 5 minutes at 4°C. Primary Abs incubated overnight at 4°C: isolectin GS-IB4 (#I21412, Thermo Fisher Scientific), the Ab 2D10, the commercially available anti-Tspan12 Ab (#LS-B9720, Lifespan Biosciences), the anti β-catenin Ab (#9562, Cell Signaling), mouse anti-Rhodopsin Ab (# MAB 5356, EMD Millipore), and rabbit anti-Red/Green opsin Ab (AB5405, EMD Millipore). Alexa fluor 488 chicken anti-rabbit IgG (#A-21441, Thermo Fisher Scientific) and goat antihuman IgG Fc cross-adsorbed secondary Ab (#SA5-10135, Thermo Fisher Scientific) were used as secondary Abs. To guarantee maximal comparability between cryosections, only central retina sections, including the optic nerve head, were collected, and representative images were taken in the central retina next to the optic nerve head.
Western Blot, Quantitative Real-Time Polymerase Chain Reaction (PCR), and PCR Array Analysis Samples were collected from single retinas or HUVECs. For Western blot analysis, lysates were denatured in Laemmli sample buffer (5 minutes at 95°C), separated by SDS-PAGE, and then transferred to nitrocellulose membranes. For quantitative real-time -PCR analysis, the following Taqman gene expression assays (Thermo Fisher Scientific) were used: mouse actin (Assay ID Mm02619580_g1), mouse Tspan12 (Mm00557112_ m1), mouse plasma lemma vesicle-associated protein ORIGINAL RESEARCH ARTICLE (Mm00453379_m1), human ACTIN (Hs01060665_g1), human bone morphogenetic protein 4 (Hs00610344_ m1), human plasma lemma vesicle-associated protein (Hs00229941_m1), human VEGF/A (Hs00900055_m1), and human CLAUDIN5 (Hs00533949_s1). For PCR array analysis, the mouse angiogenesis PCR array (#PAMM-024Z, Qiagen) was run using the RT2 SYBR quantitative real-time-PCR Mastermix (#330522, Qiagen). Data analysis was performed using the RT2 Profiler PCR array data analysis version 3.5 (Qiagen).
Overexpression of Tspan12 and Fluorescence-Activated Cell Sorting
Overall, 293 cells (#CRL-1573, ATCC) were transfected with Tspan12 (#RC206943, OriGene) for 48 hours. After transfection, cells were stained with Ab 2D10, commercial anti-Tspan12 Ab (#LS-B9720, Lifespan Biosciences), or IgG1 isotype control Ab (#110-HG-100, R&D Systems). For nuclear staining Hoechst was used. Stained cells were sorted with an LSRII flow cytometer (Becton Dickinson).
Coimmunoprecipitation
Confluent 293 cells in 75 cm
2 flasks were transfected with ag-Tspan12 (RC206943, OriGene) and FZD4 (RG217286, OriGene) using Lipo2000 (Invitrogen) for 48 hours. Cells were washed with PBS and incubated for 1 hour with or without 2D10 (1 µg/mL) at 4°C. As a control, flag-Tspan11 (RC216497, OriGene) was transfected. After 3 washes with PBS, cells were incubated with DTSSP (Pierce) in PBS for 1 hour. Cell lysates were incubated with antiflag antibody-protein A/Gbeads overnight at 4°C. After extensive washes with lysis buffer (150 mM NaCl, 50 mM Tris/HCl [pH 8.0], 1 mM EGTA, 1% NP-40, 0.1% N-dodecyl-β-d-maltoside, 3 mM MgCl 2 , and protease inhibitor cocktail), beads were eluted. Eluates were analyzed by Western blot. Antibodies used were anti-flag antibody (#A00187-200, Genscript) and Anti-FZD4 (#MAB194-SP, R&D Systems).
Ganzfeld Electroretinography (ERG)
Mice were dark-adapted overnight and subsequent procedures performed under dim red light. Mice were anesthetized by intraperitoneal injection of ketamine (60 mg/kg) and xylazine (10 mg/kg). Pupils were dilated (hydroxyamphetamine 0.25% and tropicamide 1%). Ganzfeld ERG was recorded from the corneal surface. Silver needle electrodes served as reference (forehead) and ground (tail). A Ganzfeld dome was used for stimulation (Espion E2 with Colordome, Dignosys). In the dark-adapted (scotopic) state, white flashes of increasing intensities (1x10 
Statistical Analysis
All data are presented as mean +/-standard error of the mean. Data were tested for normality using the D'Agostino-Pearson omnibus normality test. If normality was not rejected, t tests or analyses of covariance were performed. When normality was rejected, MannWhitney or Kruskal-Wallis nonparametric tests were used. Statistical tests used to determine significance as well as level of statistical significance for each experiment are indicated in the figure legends.
RESULTS
Selection and Verification of AntiTspan12 Ab
Tspan family proteins have 2 extracellular domains (ECD): a small loop (ECD1) and a big loop (ECD2). 34 Because Tspan proteins interact with other receptors mainly through the ECD2, we used the ECD2 of Tspan12 as the antigen for screening Ab using naïve human combinatorial Ab phage libraries (diversity: ≈10 9 ) ( Figure 1A ). To cover future experiments in human and mouse tissue, we designed an antigen with the common sequence of ECD2 in both species. After 3 rounds of biopanning with the Ab phage libraries, we found 6 Ab clones ( Figure 1B and 1C) . Biolayer interferometry kinetic binding analysis was used to determine the exact K d values. All 6 Abs showed high affinity with K d values in the nanomolar range ( Figure 1 and Table I in the online-only Data Supplement). To verify whether the Ab clone 2D10 binds to native Tspan12, untreated HEK-293 (WT control) cells and cells overexpressing Tspan12 (Tspan12 OE) were labeled with the Ab 2D10, showing that the fluorescent signal was stronger in the Tspan12 OE group by fluorescence-activated cell sorting analysis ( Figure 1D ). Furthermore, specific binding to the Tspan12 antigen expressed on HUVECs was tested by immunocytochemistry. The Ab 2D10 or a commercial anti-Tspan12 Ab were incubated with HUVECs (WT control), and HUVECs were treated with siRNA to KD Tspan12 expression. The Ab 2D10 stained the surface of HUVECs in similar patterns as the commercial Ab in WT control samples, whereas staining was strongly decreased in the Tspan12 KD groups ( Figure 1E and Figure II in the online-only Data Supplement) indicating that the selected Ab recognizes native Tspan12 on the surface of endothelial cells.
The Anti-Tspan12 Ab Inhibits Endothelial Cell Migration and Tube Formation
To evaluate the anti-angiogenic potential of the selected Ab clones, all 6 Ab clones were tested in vitro. In the wound-healing assay, Ab clone 2D10 most potently inhibited HUVEC cell migration ( Figure III 
The Ab 2D10 Interferes With β-CateninMediated Signaling in Endothelial Cells
Tspan12 has been shown to impact vascular development by regulating the canonical Wnt/β-catenin signaling pathway. 14 We hypothesized that the observed anti-angiogenic effects of the Ab 2D10 were mediated through inhibition of β-catenin signaling. First, we tested whether the Ab 2D10 blocks the receptor complex formation between Tspan12 and FZD4. Coimmunoprecipitation experiments confirmed that Tspan12 and Figure 3A) , implying that the Ab 2D10 specifically interrupts the interaction between FZD4 and Tspan12. We next tested whether Ab 2D10 treatment blocked β-catenin signaling. Immunocytochemistry staining and Western blot analysis confirmed significant downregulation of β-catenin (Figure 3B through 3D ) and upregulation of Naked2 ( Figure  VI in the online-only Data Supplement), an important antagonist of β-catenin signaling after Ab 2D10 treatment. mRNA expression levels of bone morphogenetic protein 4, a confirmed direct β-catenin target and potent inducer of endothelial cell proliferation and migration, 35 was significantly downregulated, whereas VEGF/A levels remained unchanged in response to Ab treatment, suggesting that the Ab 2D10 interferes with VEGF-independent angiogenic factors ( Figure 3E ). Furthermore, plasma lemma vesicle-associated protein, an established marker for impaired β-catenin signaling, 14 was significantly upregulated ( Figure 3E ), whereas expression levels of CLAUDIN5, which is known to be upregulated in areas of disturbed blood-retinal barrier function in Norrin, FZD4, LRP5/6, or β-catenin KO mice, 10, 11, 36 remained unaltered. These differences may be attributed to either differences in the upstream target (Norrin, FZD4, LRP5 versus Tspan12) or to the fact (1 µg/mL). Tspan12 was pulled down and its interaction with FZD4 analyzed by Western blot. Interactions between Tspan12 and FZD4 were significantly reduced after incubation with the Ab 2D10. Representative results of 3 independent experiments were analyzed by densitometry. MannWhitney test. *P<0.05. Immunocytochemistry (B) and Western blot (C) analyses showed significant downregulation of β-catenin protein levels after treatment with Ab 2D10. D, Quantitative measurement of (C) by densitometry. n=2, *P<0.05, Kruskal-Wallis test with Dunn's multiple comparisons test. E, Ab 2D10 treatment significantly decreased expression levels of bone morphogenetic protein 4 (BMP4), whereas plasma lemma vesicle-associated protein (PLVAP) levels were significantly upregulated as expected because intact β-catenin signaling suppresses PVLAP expression.
14 Expression levels of vascular endothelial growth factor (VEGF) or CLAUDIN5 remained unaffected. n=3, *P<0.05, 2-way analysis of variance with Sidak's multiple comparisons test,Scale bar: 100 µm.
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that Ab-mediated inhibition of target genes may have a weaker impact on downstream signaling pathways than genetic KO models.
Inhibition of Tspan12 Delays Vascular Development and Attenuates Neovascular Changes in Retinal Vasoproliferative Disease
To confirm in vivo efficacy of the Ab 2D10, we next tested its effect on retinal vascular development. Figure 4A shows that intravitreal injection of the Ab 2D10 at postnatal day 2 (P2) resulted in a mild but significant reduction of the vascularized area at P6 compared with control-treated eyes. Likewise, intravitreal injection of the Ab 2D10 after the formation of the superficial vascular plexus at P7 potently suppressed the deep plexus formation represented by a significant decrease in vascular branching points (Figure 4B) . Observed effects closely resembled the vascular phenotype of Tspan12 KO mice, 14 suggesting that the Ab 2D10 maintains the previously observed antiangiogenic potential in vivo.
Although the role of Tspan12 during retinal vascular development has been well characterized, not much is currently known about its function in retinal vasoproliferative diseases. Thus, we tested whether inhibition of Tspan12 with the Ab 2D10 shows therapeutic potential for the treatment of retinal vasoproliferative disease. The OIR and VLDLR KO mouse models represent animal models of human inner and outer retinal vasoproliferative diseases. 37, 38 In the OIR model, the retina is characterized by a central VO area and hypoxia-induced preretinal NV changes that originate from the superficial vascular plexus. The efficacy of a therapeutic agent can be measured by its potential to reduce NV (outlined in red in Figure 4C ) and to enhance capillary regrowth indirectly measured by the VO area (outlined in yellow). Intravitreal injection of the Ab 2D10 at OIR P12 significantly decreased both NV and VO at OIR P17. The Ab 2D10 thus functions as an angiomodulator rather than an anti-angiogenic agent in vivo by facilitating capillary regrowth while inhibiting pathological NV.
In contrast to the OIR model, VLDLR KO mice develop neovascular changes that originate from the deep and intermediate vascular plexus and grow toward the subretinal space. 38 Intravitreal injections of the Ab 2D10 at P15 significantly reduced vascular tuft formations in this second model of pathological NV ( Figure 4D ).
Safety studies testing retinal function with ERG at P32 after intravitreal injection of the Ab 2D10 (P12) showed no signs of negative side effects of the Ab treatment ( Figure VII in the online-only Data Supplement). In addition, mRNA-based gene expression analysis did not suggest any inflammatory responses to the Ab treatment compared with IgG1-treated controls (Table II in 
The Ab 2D10 Inhibits β-Catenin Signaling in Vivo
In the experiments described earlier, we observed that Ab-mediated inhibition of Tspan12 suppressed the development of pathological NV in vivo ( Figure 4C and 4D) and modulated β-catenin signaling in vitro (Figure 3) . To gain more insight into the role of Tspan12/β-catenin signaling in retinal vasoproliferative disease, we then set out to determine whether Tspan12/β-catenin signaling was endogenously activated in those models. In the OIR model, mRNA (OIR P12 6 hours) and protein levels (OIR P13) of Tspan12 were significantly upregulated during the early hypoxic phase compared with P12 0 hours ( Figure 5A and 5B). Likewise, protein levels of β-catenin were also significantly increased at P13 compared with P12 ( Figure 5C ). The time between OIR P12 and OIR P13 is particularly interesting because it marks the acute onset of retinal hypoxia within the central VO. 39 These data suggest that the Tspan12/β-catenin signaling pathway is activated in response to the acute onset of retinal hypoxia and may, thus, play an important role in the early phase of hypoxia-driven preretinal NV. In contrast, VLDLR KO mice characterized by chronic development of intraretinal NV ( Figure 5D ) 38 showed significant increases in retinal Tspan12 and β-catenin levels at later stages around P21 (mRNA) and P32 (mRNA and protein) compared with WT controls (Figure 5D through 5F).
To confirm that the Ab 2D10 localizes to the vascular bed in vivo, the Ab 2D10 was injected intravitreally and then detected with an antihuman IgG1 (Fc) secondary antibody in retinal whole mounts. Retinal vessels were clearly labeled in eyes treated with the Ab 2D10 ( Figure 6A ). Furthermore, 6 hours after intravitreal treatment with the Ab 2D10, retinal β-catenin levels were significantly decreased compared with IgG1 control-treated eyes in the OIR as well as the VLDLR KO model ( Figure 6B ). When expression of VEGF signaling-associated genes was analyzed after the Ab 2D10 treatment, no changes were detected (Table II in the online-only Data Supplement). Taken together, these data suggest that Tspan12/β-catenin signaling plays a role in the development of vascular abnormalities and Ab 2D10 induces its angiomodulatory effects by controlling the β-catenin signaling pathway in vivo as well as in vitro. 
Combination of the Ab 2D10 With the Anti-VEGF Agent Enhances the Therapeutic Potential of Each Monotherapy
VEGF inhibitorssuch as Aflibercept currently represent the gold standard for the treatment of vasoproliferative disease. Thus, we compared the angiomodulatory effect of the Ab 2D10 with Aflibercept in rodent models of retinal vascular proliferation. Dose response experiments in the OIR model revealed that the Ab 2D10 most strongly reduced the VO and NV areas at doses between 0.2 ng and 75 ng ( Figure 7A ). Maximal rescue effects induced by the Ab 2D10 were observed at 45% for the VO and 68% for the NV. In contrast, Aflibercept showed the highest efficacy at doses of 2 µg, improving the VO by 37% and the NV by 80%. Further increases in Aflibercept dosage ≤20 µg did not result in additional enhancement of the therapeutic effect. Overall, Aflibercept doses in all treatment groups were ≈100-fold higher than the Ab 2D10 doses. Although the therapeutic potential of Aflibercept to prevent preretinal NV was superior to the Ab 2D10, our Ab showed better rescue effects regarding capillary regrowth. Because the Ab 2D10 and Aflibercept appear to exhibit complementary activity regarding their therapeutic effect and affected signaling pathways, combination therapy of both could provide synergistic therapeutic potential and possibly allow for a reduction of Aflibercept dosing. Figure 7B shows that low doses of Aflibercept (20 ng) resulted in a weak reduction of the VO (38%) and NV (26%) areas, whereas the Ab 2D10 (10 ng) decreased the VO and NV areas by 40% and 41%, respectively. However, combined intravitreal injection of Aflibercept (20 ng) plus the Ab 2D10 (10 ng) increased the rescue effect on VO and NV areas to 64% and 75%, respectively. These data confirm that the combination therapy of the Ab 2D10 and Aflibercept significantly enhances the therapeutic potential of each monotherapy and allows reduction of Aflibercept dosing. 
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Side Effects on Retina Functions Through Anti-VEGF Agents Can Be Alleviated by Combining Low Doses of It With the Ab 2D10
New options to decrease anti-VEGF dosing are of great clinical relevance because long-term suppression of VEGF signaling below physiological levels can negatively affect the neuroretina 40, 41 and potentially cause systemic side effects. 42 We assessed the risk for off-target effects of Aflibercept treatment by testing retina function by ERG at P32 after intravitreal treatment at OIR P12 and compared it to the effect of low-dose combination therapy. Previous studies have shown that retina function assessed by ERG is significantly impaired for ≤6 weeks after OIR. 43 Our data confirmed that scotopic b-wave amplitudes ( Figure 8A ) and photopic responses ( Figure  VIIIA in the online-only Data Supplement) were significantly decreased in OIR IgG1-treated eyes compared with age-matched normoxia controls. It is important to note that the human equivalent Aflibercept doses (2 µg) further impaired scotopic b-wave (and weakly a-wave) amplitudes in mice compared with IgG1-treated controls ( Figure 8 and Figure VIIIA in the online-only Data Supplement). The human equivalent treatment dose of Aflibercept in mice was determined as 2 µg based on the anatomic proportion between mouse and human eyes of ≈1:1000. These data suggest that excessive deprivation of VEGF signaling negatively affects inner retina function, whereas rod photoreceptors are less afflicted. However, a combination of low-dose Aflibercept (20 ng) with low-dose Ab 2D10 (10 ng) did not result in negative effects on scotopic ERG compared with OIR IgG1 controls while maintaining significant rescue effects on the vascular phenotype at OIR P17 ( Figure 7B ). Consistent with the ERG data, immunohistochemistry staining showed no obvious changes in the rhodopsin-staining pattern in all treatment groups (Figure VIIIB in the online-only Data Supplement). Thus, rod photoreceptors remain largely unaffected by OIR and Aflibercept (2 µg) treatment, whereas cone photoreceptors visualized by red/green opsin staining were most strongly affected in the Aflibercept treatment group. Overall, retinas from Aflibercept-treated OIR eyes also appeared thinner and lacked clear organization of the vascular bed into 3 distinct layers compared with normoxia controls and combination therapy. These aspects further strengthen the clinical relevance of combination therapies and the therapeutic potential of the Ab-mediated inhibition of Tspan12 for the treatment of vasoproliferative disease.
DISCUSSION
To our knowledge, this study is the first to show that Tspan12/β-catenin signaling plays a key role in retinal vasoproliferative diseases and that uses Tspan12 as target for the treatment of vasoproliferative retinopathy. We developed a blocking Ab against Tspan12 using a phage displayed combinatorial human Ab library and provide strong evidence for its anti-angiogenic effects on vascular endothelial cells in vitro (Figures 1 and 2 ) and its angiomodulatory potential in 3 different in vivo models (Figure 4) . ERG analysis showed no signs of negative side effects on retina function because of . This finding correlates well with the fact that Tspan12 is selectively expressed on retinal vascular endothelial cells, 14 making Tspan12 Ab treatment unlikely to induce off-target effects. Because of its complimentary activity to anti-VEGF agents, the Ab 2D10 showed significant enhancement of the therapeutic potential in combination therapy with anti-VEGF treatments ( Figure 7B ) and provides a new opportunity to decrease necessary therapeutic doses of anti-VEGF agents.
Broad cross-species reactivity is an important aspect for the use of therapeutic Abs in preclinical studies. To investigate their effect and mode of action in mouse and human tissues, we chose an ECD2 region common to both species as target region for Tspan12 Ab binding. Immunofluorescence analysis indicated that the 2D10 Ab specifically interacts with vascular endothelial cells in the mouse retina as well as human endothelial cells such as HUVECs. According to kinetics and interaction analysis, the affinity of the Ab 2D10 to the target was high (K d : 8.44 nmol/L). In addition, the Ab 2D10 showed no particular side effect in vivo ( Figure VII and Table II in the online-only Data Supplement). Further optimization through affinity maturation and optimization of Ab dosing may even enhance the activity of the Ab 2D10.
Rodent models naturally do not encompass all aspects of common human vasoproliferative diseases such as diabetic retinopathy, retinal vein occlusion, or retinal angiomatous proliferation. However, the OIR model is currently the only rodent model that reliably develops preretinal NV and offers the opportunity to simultaneously test the effect of new angiomodulatory agents on pathological NV and capillary regrowth. 37 Acute onset of retinal hypoxia represents the main stimulus for the angiogenic processes observed in the OIR model. In contrast, the VLDLR KO model develops persistent intraretinal neovessels that cause dysregulation of photoreceptor metabolism and progressive photoreceptor loss. 38, 44 In combination, these 2 rodent models cover many different aspects that contribute to human retinal vasoproliferative diseases. The high efficacy of the Ab 2D10 in both models promises great therapeutic value of the Ab 2D10 for human retinal diseases.
In this study, we showed for the first time that activation of the Tspan12/β-catenin signaling pathway is associated with acute hypoxia-induced vascular changes ( Figure 5A through 5C) as well as chronic neovascular changes because of metabolic imbalance ( Figure 5D through 5F). Previous studies have repeatedly suggested that Wnt/β-catenin signaling plays an important role in retinal vasoproliferative disease. 20, 21 However, β-catenin mediated signaling is complex including Wnt-unrelated agonists like Norrin. Modulation of β-catenin-associated agonists for the treatment of proliferative retinopathy has so far yielded heterogeneous results. Although Ohlmann et al 45 showed that constitutive ectopic overexpression of Norrin ameliorates the vascular phenotype in the OIR model, studies testing injectable antagonists to the Wnt/β-catenin pathway provided strong evidence that inhibition of β-catenin signaling improved vascular changes in models of proliferative retinopathy. 23, 46 The controversy in these results may be explained by the fact that constitutive overexpression of Norrin in transgenic mice initially affected the development of the avascular area so that observed improvements in preretinal NV at later time points represented secondary effects to an initially altered VO. In general, genetic KO/overexpression models may also be affected by compensatory changes in other signaling pathways, which in turn influence the overall phenotype. In contrast, intravitreal injections of the Ab 2D10 induced a sudden decrease in β-catenin signaling ( Figures 3B through 3D and 6B) at a time of increased endogenous β-catenin activity ( Figure 5C ).
The therapeutic success of the Ab 2D10 treatment may also be attributed to a reduction rather than complete inhibition of the β-catenin signaling pathway. The idea of normalizing an overactivated signaling pathway would also explain the difference between the pure angiostatic effects observed in vitro, where basal β-catenin activity represents an important driver of endothelial cell proliferation and the angiomodulatory function of the Ab seen in vivo where Tspan12/β-catenin signaling is activated. Dose-response experiments suggest that moderate inhibition of β-catenin signaling may yield the better outcome ( Figure 7A ). Complete inhibition of Tspan12/β-catenin may suppress endothelial cell proliferation more strongly and hence negatively affect capillary regrowth similar to high doses of Aflibercept (>2 µg).
Anti-VEGF agents have shown great therapeutic success in the treatment of retinal edema because they effectively decrease vascular permeability of abnormal neovessels. However, their efficacy regarding regression of existing neovessels and prevention of neovessel formation as stand-alone therapy in proliferative diabetic retinopathy is less well studied and limited by their shortterm effects. 2, 47 Also in the treatment of age-related macular degeneration, open questions about long-term visual outcomes, 48 nonresponders to anti-VEGF agents, 49 and potential long-term side effects 42, 50 remain. In accordance with previously published studies, 41 our ERG data showed that human equivalent treatment doses (2 µg) of Aflibercept negatively affected inner retina ( Figure 8 ) and cone photoreceptor function and morphology (Figure VIII in the online-only Data Supplement). Our observation that cone photoreceptors are more susceptible to VEGF deprivation than rods confirms results from previous studies showing that VEGF-A KO induces degeneration of cone but not rod photoreceptors. 40 These results make it even more urgent to establish new therapeutic agents that substitute or complement anti-VEGF agents.
Doses for anti-VEGF agents should be decreased to a minimum so that the rod and cone photoreceptor function are not adversely influenced by the angiomodulatory therapy in the long run.
